PK resource core to speed anticancer drug development
Official title: PITT-CAL ETCTN PK Resource Laboratory
Funded at Beckman Research Institute/city of Hope · NIH-11500898 · Data updated 2026-11-12
A national collaboration of two cancer center labs provides advanced drug-kinetics testing to support new anticancer agents in early clinical trials.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | January 1, 2025 |
| Project end | February 28, 2027 |
| Funding year | 2026 |
| Award (this year) | $523,424 |
| NIH project number | 3U24CA247643-06S1 |
| Project ID | NIH-11500898 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients could benefit indirectly through faster, better-informed clinical trials of anticancer agents.
✕Less likely to help
There is no direct treatment or diagnostic procedure for patients in this grant; benefits arise from improved research support.
What this research studies
This grant funds a joint PK resource lab to harmonize and accelerate how we measure how anticancer drugs move through the body. It supports designing PK studies, analyzing biological samples, and performing various PK analyses so trial teams can make informed decisions quickly. The goal is to deliver precise, timely pharmacology data that complements other clinical and correlative studies in the ETCTN network. This is about making drug development faster and more reliable for patients; it is not a patient treatment itself.
Why it matters
Potential benefit: If successful, clinicians will have better PK data to choose dosing and schedules for cancer drugs, potentially improving safety and effectiveness for patients.
How similar studies have gone: Other PK cores in cancer networks have improved drug development timelines and data quality in past collaborations.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Synold, Timothy W — Beckman Research Institute/city of Hope
- Study coordinator: Synold, Timothy W
Related research
Other NIH-funded projects on the same topics.
-
Targeting the protein-assembly that drives AML growth
Aiming to slow or stop acute myeloid leukemia by blocking how cancer cells make proteins.
-
Metformin for reversing accelerated aging in young adults with metabolic health issues
A practical plan to use metformin to help 18- to 35-year-olds with insulin resistance improve metabolic health and slow aging.
-
PIN1-targeted therapy for pancreatic cancer
A team is developing new PIN1 inhibitors to treat pancreatic cancer that tends to resist current therapies.
-
DNA mismatch repair defects and anti-tumor immunity in cancer
Researchers are studying how defects in a DNA repair system affect the body’s immune response to tumors, to improve cancer treatments that use the immune system.
-
Understanding how skin cancer-associated fibroblasts affect immune detection in early mycosis fungoides
This grant investigates how certain skin cells in early mycosis fungoides might help the cancer hide from the immune system, with findings aiming to improve future patient care.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.